Abstract
Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have